{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.83","upperLimit":"5.06","value":"4.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Mean duration of response in months. Estimated using the method of Kaplan-Meier.","dispersionType":"Full Range","groups":[{"description":"Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"AZD6244 (Selumetinib) Treatment"}],"paramType":"MEAN","populationDescription":"All participants with response","reportingStatus":"POSTED","timeFrame":"From response to disease progression or death, assessed up to 2 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}